April 22, 20250CommentsCytonics Announces Initiation Of First-In-Human Phase 1 Clinical Study For CYT-108 In Patients Suffering From Osteoarthritis Of The Knee
April 22, 20250CommentsCytonics Announces Completion Of Enrollment For Phase 1 Clinical Study Evaluating CYT-108, A Novel Recombinant Protease Inhibitor, In Patients Suffering From Osteoarthritis Of The Knee
April 22, 20250CommentsCytonics Announces Successful Completion of Phase 1 Study for First Nine Patients in CYT-108 Clinical Trial
April 22, 20250CommentsCytonics Announces Launch of Regulation A+ Equity Crowdfunding Campaign to Fund Phase 2 Development
March 25, 20250Comments#47 🪙Cytonics Announces Launch of Regulation A+ Equity Crowdfunding Campaign to Fund Phase 2 Development
